Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company has received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing it for commercial sale in Europe. The seventh generation of the ReWalk, which includes innovative new and enhanced features such as cloud connectivity, push-button control, customizable walking speeds, and seamless activation of stairs and curbs, will now be available to European customers, who currently represent approximately 40% of Lifeward’s exoskeleton sales. The majority of these sales are generated through Lifeward GmbH, where the process of reimbursement for personal exoskeletons has been broadly established for individuals in Germany.

Read more at globenewswire.com